Positive results of a study into the effects of an add-on to antipsychotics for the management of treatment-resistant schizophrenia (TRS) have been announced by Newron Pharmaceuticals.
The unique glutamatergic mechanism of action in Newron Pharmaceuticals’ investigational new drug can potentially produce a long-lasting antipsychotic response in patients with TRS, and the benefits will accrue over time.